Three Years After CARMENA: What Have We Learned?

Eduard Roussel; Benoit Beuselinck; Maarten Albersen

doi:10.1016/j.eururo.2021.07.007

Three Years After CARMENA: What Have We Learned?

Eur Urol. 2021 Oct;80(4):425-427. doi: 10.1016/j.eururo.2021.07.007. Epub 2021 Jul 27.

Authors

Eduard Roussel¹, Benoit Beuselinck², Maarten Albersen³

Affiliations

¹ Department of Urology, University Hospitals Leuven, Leuven, Belgium. Electronic address: eduard.roussel@uzleuven.be.
² Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.
³ Department of Urology, University Hospitals Leuven, Leuven, Belgium.

PMID: 34325948
DOI: 10.1016/j.eururo.2021.07.007

Abstract

Cytoreductive nephrectomy makes way for more effective systemic treatments in the current mRCC treatment paradigm, as disease volume and the number of IMDC risk factors increase. Careful patient selection for upfront or deferred cytoreductive nephrectomy based on these criteria remains key.

Keywords: Cytoreductive nephrectomy; Renal cell carcinoma.

Publication types

Editorial
Comment

MeSH terms

Carcinoma, Renal Cell* / drug therapy
Carcinoma, Renal Cell* / surgery
Cytoreduction Surgical Procedures
Humans
Kidney Neoplasms* / drug therapy
Kidney Neoplasms* / surgery
Nephrectomy
Treatment Outcome